Skip to content
CSE: XRX.CN 0.14 0.00 0.00%  
XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

callout-three

callout-three

Leave a Reply Cancel reply

Your email address will not be published.

Press Releases

  • XORTX Provides Program Update Regarding XRx-008 for ADPKD and XRx-101 for Coronavirus / COVID-19 Programs May 19, 2020
  • XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus / COVID-19 Clinical Trials April 30, 2020
  • XORTX Provides Overview and Update of Key Activities April 30, 2020
  • XORTX Announces New Clinical Advisory Board Member March 26, 2020
  • XORTX Launches XRx-101 Following the Filing of a Provisional Patent to Potentially Treat Respiratory and Kidney Disease Injury Due to Coronavirus Infection March 16, 2020
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress